Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Robert S. Witte"'
Autor:
Robert S. Witte, John S. Witte
Drawing upon over 40 years of experience, the authors of Statistics, 11th Edition provide students with a clear and methodical approach to essential statistical procedures. The text clearly explains the basic concepts and procedures of descriptive
Autor:
Robert S. Witte, John S. Witte
Drawing upon over 40 years of experience, the authors of Statistics, 10th Edition provide business professionals with a clear and methodical approach to essential statistical procedures. The text clearly explains the basic concepts and procedures of
Autor:
Robert S. Witte, Peter A. Beatty, James McGovern, Joan H. Schiller, Tien Hoang, Gary Shapiro, Paul L. Koch, Maria Quisumbing, Anthony Jaslowski, KyungMann Kim
Publikováno v:
Lung Cancer. 42:97-102
Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite a dramatic initial response, however, most patients relapse. Given the activity of gemcitabine in non-small cell lung cancer (NSCLC), and early clinical trials suggesting acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f559cc55c67a51ca130b77137c9af34
https://doi.org/10.1016/s0169-5002(03)00273-3
https://doi.org/10.1016/s0169-5002(03)00273-3
Autor:
Robert S. Witte, Allan J. Schutt, Edward Barylak, Jules E. Harris, Avital Cnaan, Edward G. Mansour
Publikováno v:
Cancer. 91:1020-1028
BACKGROUND The authors conducted a randomized Phase III trial of three treatment regimens for patients with residual, nonmeasurable, intra-abdominal metastatic disease after undergoing resection for primary colorectal carcinoma. METHODS To be eligibl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92a073216ee24088dfb9cde8538b4314
https://doi.org/10.1002/1097-0142(20010301)91:5<1020::aid-cncr1093>3.0.co
https://doi.org/10.1002/1097-0142(20010301)91:5<1020::aid-cncr1093>3.0.co
Publikováno v:
Southern Medical Journal. 93:916-919
A 52-year-old man with retroperitoneal nodal, lung, and liver metastases from choriocarcinoma received chemotherapy with etoposide, cisplatin, and bleomycin. Within 48 hours of starting treatment, he had hypotension, hypoxemia, and anuria. Laboratory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98855788ecc0c0ce44d8cb602c451047
https://doi.org/10.1097/00007611-200093090-00017
https://doi.org/10.1097/00007611-200093090-00017
Autor:
Thomas J. Smith, Robert F. Asbury, Charles M. Strnad, Thomas L. Goodman, Daniel G. Haller, Stuart R. Lipsitz, Robert S. Witte, George Wilding
Publikováno v:
Investigational New Drugs. 17:173-177
Twenty-four previously untreated, ambulatory patients with advanced colorectal carcinoma were treated with either caracemide (11 patients) or homoharringtonine (13 patients). No objective responses were observed in any of the treatment cohorts. Carac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39005a3262e3b8c03d5804f8d6d0847f
https://doi.org/10.1023/a:1006327418043
https://doi.org/10.1023/a:1006327418043
Publikováno v:
Investigational New Drugs. 16:315-318
Seventy-three eligible, chemotherapy-naive, ambulatory patients with advanced pancreatic carcinoma were allocated to one of two treatment regimens: 35 received PALA (1250 mg/m2 daily x 5 every 4 weeks) and 38 were given SAM (streptozotocin 400 mg/m2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::720c7d3da0314963a71bf56a0e07b4c4
https://doi.org/10.1023/a:1006292218890
https://doi.org/10.1023/a:1006292218890
Publikováno v:
Investigational New Drugs. 14:409-413
Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815bee922429cce8a6cac9d6aea320fe
https://doi.org/10.1007/bf00180819
https://doi.org/10.1007/bf00180819
Publikováno v:
Investigational New Drugs. 12:255-258
The antitumor activity and toxicity of trimetrexate (TMTX) was evaluated in measurable, hormone-refractory, advanced prostate cancer patients. Patients were required to have an ECOG performance status3, bidimensionally measurable disease, serum creat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e4c0ca7157fc40446be488effbc382
https://doi.org/10.1007/bf00873968
https://doi.org/10.1007/bf00873968
Publikováno v:
Cancer. 73:688-691
BACKGROUND Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated. METHODS Ambulatory patients with advanced urothelia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3520e6d61dc31424d77462e5e3d38ab
https://doi.org/10.1002/1097-0142(19940201)73:3<688::aid-cncr2820730330>3.0.co
https://doi.org/10.1002/1097-0142(19940201)73:3<688::aid-cncr2820730330>3.0.co